It is not a new formula for this industry; the revenue addition from this partnership is more beneficial to the taxi services than a brokerage firm that helps the customers. Unless a concept notably drives the revenue revival to the next level, it is not a meaningful effort from one point of view. I believe they deliberately come up in the news unless promoters stakes are liquidated to further levels.
Posts in category Value Pickr
DE NORA INDIA, poised for growth (10-08-2023)
Electrodes are required for manufacturing Green hydrogen & it’s a consumable & will be fully used up in 3 years, but life of these electrodes can be prolonged by recoating.
Denora manufacturers electrodes for all requirements, as well as recoating thru Annual maintenance contract to prolong the life span of electrodes.
Denora has run up substantially from levels of ₹140 to 250, 4 years back. It’s a cyclical business with periods of peak & under performance. At current levels best to book profit. Fresh buying not advised
Lincoln Pharma … the next mid-cap pharma in the making …? (10-08-2023)
Q1FY24 result update
| Particulars | Q1FY24 | Q1FY23 | YoY | Q4FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue | 136 | 123 | 10.5% | 112 | 21% |
| EBITDA | 21 | 17 | 23.5% | 17 | 23.5% |
| Margin | 15.4% | 13.8% | 160 bps | 15.17% | 23 bps |
| PAT | 19 | 15 | 26% | 13 | 46% |
Disclosure: Tracking not invested
Natco Pharma: Focusing On Complex Products (10-08-2023)
Market price is always forward looking it is trading above 60% of 200 DMA, that itself says current price is priced in. When the price doesn’t move after good set that is the peak , in order continue the journey from there it has to either maintain or outperform the growth compared to previous quarters. All know revlimid contribution is going to add a lot to the top and bottomline , now other players are entered (at the moment Reddys and many others will join soon ) market will be skeptical.
Kothari Petrochem Ltd~ A hidden moated small-cap company? (10-08-2023)
Extraordinary results by kothari petrochem when other chemical cos (dependent on crude derivatives as raw materials) have reported poor nos.
OutcomeofBoardMeeting09082023_09082023123955.pdf (2.2 MB)
~Revenues up 2X (yoy)
~ Profits up 5X ( yoy)
Commissioning an INR 6Crs pilot plant in manali for HR-PIB production which will diversify its revenue profile & help in margin improvement.
RPSG Ventures – A proxy IT play and an emerging FMCG company (10-08-2023)
Amazing results. All thanks to their IPL stake. YOY growth in EBIT from 155 Crs. to 406 Crs. This will go even higher as they build their brand value.
Natco Pharma: Focusing On Complex Products (10-08-2023)
The market has not awarded for the results published. What could be the possible reasons ?
Let’s try and list it to generate variant perceptions.
- Lack of liquidity ? Ie. Sectoral tailwinds missing.
Manappuram Finance (10-08-2023)
Manappuram Finance Ltd
NII Rs. 1377.9 Cr vs YoY Rs. 997.4 Cr, QoQ Rs. 1182.6 Cr
Provision Rs. 121.2 Cr vs YoY Rs. 128.3 Cr, QoQ Rs. 47.4 Cr
PAT Rs. 495.9 Cr vs YoY Rs. 282.1 Cr, QoQ Rs. 413.4 Cr
NPA 1.24% vs QoQ 1.1%
StageInvesting +Elliot Waves (10-08-2023)
Hello @StageInvesting
What are your thoughts on HANGSENG index chart?
KRBL- The King of Basmati rice (10-08-2023)
buy back via tender …
“Approved the offer to Buy-back up to 65,00,000 (Sixty-Five lacs only) fully paid-up
Equity Shares of Face Value of ₹1/- (Rupee one only) each of the Company, representing
approximately 2.76% of the total number of equity shares in the total paid-up equity share
capital of the Company, for an aggregate amount not exceeding ₹32,500 Lacs (Rupees
Thirty-Two Thousands Five Hundred Lacs only) (hereinafter referred to as the
“Buyback Size”), which is 6.94% and 6.96% of the aggregate of the fully paid-up Equity
Share capital and free reserves (including securities premium) as per the latest audited
standalone and consolidated financial statements of the Company as on 31st March 2023,
respectively, at ₹500 (Rupees Five-Hundred only) per Equity Share (the “Buyback
Price” and such buyback, the “Buyback”).
The Buyback Size does not include any expenses incurred or to be incurred for the purpose
of undertaking the Buyback, including but not limited to the filing fees, advisory fees,
public announcement publication expenses, printing and dispatch expenses, transaction
costs viz. brokerage, applicable taxes such as buyback tax, securities transaction tax, goods
and service tax, stamp duty, etc. and other incidental and related expenses.
The buyback is proposed to be undertaken through the tender offer route using the stock
exchange mechanism notified by SEBI vide circular CIR/CFD/POLICYCELL/1/2015
dated 13 April 2015, as amended, read with thecirculars issued in relation thereto, including
the circular CFD/DCR2/CIR/P/2016/131 dated 09th December 2016, circular
SEBI/HO/CFD/DCR-III/CIR/P/202l/615 dated 13th August 2021 and circular
SEBI/HO/CFD/PoD-2/P/CIR/2023/35 dated 08th March 2023, and such other
circulars as may be applicable, including any amendment thereof, in accordance with the
provisions contained in the SEBI (Buy-Back of Securities) Regulations, 2018 (hereinafter
referred to as the “Buyback Regulations”) and the Companies Act, 2013, as amended,
and rules made thereunder.
Fixation of Record Date: Pursuant to Regulation 42 of the SEBI Listing Regulations and
Regulation 9(i) of the Buyback Regulations, the Board has fixed Friday 25th August 2023,
as the record date for the purpose of determining the entitlement and names of the
shareholders eligible to participate in the Buyback.
The Board took note of the intention of the members of thThe Board took note of the intention of the members of the promoter & promoters group
to participate in the Proposed Buyback. The Board has also approved the constitution of
a Buyback Committee with regard to the proposed Buyback and has delegated its powers
to do such acts, deeds, matters, and things as it may, in its absolute discretion, deem
necessary, expedient, usual or proper in relation to the proposed Buyback”